ATE422362T1 - Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose - Google Patents

Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose

Info

Publication number
ATE422362T1
ATE422362T1 AT02788511T AT02788511T ATE422362T1 AT E422362 T1 ATE422362 T1 AT E422362T1 AT 02788511 T AT02788511 T AT 02788511T AT 02788511 T AT02788511 T AT 02788511T AT E422362 T1 ATE422362 T1 AT E422362T1
Authority
AT
Austria
Prior art keywords
cop
lateral sclerosis
amyotrophic lateral
vaccines
treating amyotrophic
Prior art date
Application number
AT02788511T
Other languages
English (en)
Inventor
Michal Eisenbach-Schwartz
Esther Yoles
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE422362T1 publication Critical patent/ATE422362T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT02788511T 2001-12-06 2002-12-05 Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose ATE422362T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33613901P 2001-12-06 2001-12-06

Publications (1)

Publication Number Publication Date
ATE422362T1 true ATE422362T1 (de) 2009-02-15

Family

ID=23314742

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02788511T ATE422362T1 (de) 2001-12-06 2002-12-05 Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose

Country Status (24)

Country Link
US (1) US7351686B2 (de)
EP (1) EP1429800B1 (de)
JP (1) JP4542339B2 (de)
KR (1) KR20040081431A (de)
CN (2) CN102151330B (de)
AT (1) ATE422362T1 (de)
AU (1) AU2002353486B2 (de)
CA (1) CA2469092C (de)
CY (1) CY1109044T1 (de)
DE (1) DE60231131D1 (de)
DK (1) DK1429800T3 (de)
ES (1) ES2322566T3 (de)
HK (1) HK1067043A1 (de)
HU (1) HU228207B1 (de)
IL (1) IL160105A0 (de)
IS (1) IS2670B (de)
MX (1) MXPA04005537A (de)
NO (1) NO336231B1 (de)
NZ (1) NZ533356A (de)
PL (1) PL205469B1 (de)
PT (1) PT1429800E (de)
RU (1) RU2303996C2 (de)
SI (1) SI1429800T1 (de)
WO (1) WO2003047500A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
CN1758922A (zh) * 2003-01-07 2006-04-12 耶达研究及发展有限公司 用于治疗性免疫接种的含共聚物1的滴眼用疫苗
EP2301569B1 (de) 2003-11-12 2018-05-02 Yeda Research and Development Co. Ltd. Impfstoff und Verfahren zur Behandlung neurodegenerativer Krankheiten
PT1701730E (pt) 2003-12-09 2013-11-27 Yeda Res & Dev Método e vacina compreendendo copolímero 1 para tratamento de distúrbios psiquiátricos
WO2005084377A2 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
CA2565703A1 (en) * 2004-05-07 2005-12-22 Peptimmune, Inc. Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
EP1910827A4 (de) * 2005-07-15 2010-02-03 Novartis Ag »pamps - mit pathogenen assoziierte molekulare muster
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
EP2195008A1 (de) 2007-09-24 2010-06-16 Hadasit Medical Research Services & Development Ltd. Verwendung von copolymer 1 zur behandlung von muskeldystrophie
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ609938A (en) 2010-10-11 2015-11-27 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
EP2699317B1 (de) 2011-04-21 2016-08-10 Mapi Pharma Limited Zufallspentapolymer zur behandlung von autoimmunkrankheiten
US8815511B2 (en) 2011-10-10 2014-08-26 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
US9861686B2 (en) * 2011-12-05 2018-01-09 Ben-Gurion University Of The Negev Research & Development Authority Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS)
WO2013144957A1 (en) * 2012-03-26 2013-10-03 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression
EP2892353A4 (de) 2012-09-10 2016-10-26 Yeda Res & Dev Individualisierte immunmodulationstherapie für neurodegenerative erkrankungen, zns-läsionen sowie altersbedingte demenz
EP3600553A4 (de) 2017-03-26 2020-09-02 Mapi Pharma Ltd. Glatiramerdepotsysteme zur behandlung progressiver formen von multipler sklerose

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3849650A (en) 1973-03-29 1974-11-19 Picker Corp Automatic x-ray inspection system
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
SE505316C2 (sv) 1995-10-17 1997-08-04 Kenneth G Haglid Användning av proteinet S-100b för framställning av läkemedel för nervceller
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20030108528A1 (en) * 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1039929A1 (de) 1998-07-21 2000-10-04 YEDA RESEARCH AND DEVELOPMENT Co. Ltd. Aktivierten t-zellen und deren verwendung
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
WO2001052878A2 (en) * 2000-01-20 2001-07-26 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
US20020037848A1 (en) * 2000-06-07 2002-03-28 Michal Eisenbach-Schwartz Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
US6835711B2 (en) * 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy

Also Published As

Publication number Publication date
IS2670B (is) 2010-09-15
SI1429800T1 (sl) 2009-08-31
WO2003047500A2 (en) 2003-06-12
MXPA04005537A (es) 2004-11-01
DK1429800T3 (da) 2009-04-27
US20050220802A1 (en) 2005-10-06
ES2322566T3 (es) 2009-06-23
EP1429800A2 (de) 2004-06-23
AU2002353486B2 (en) 2009-01-15
CN1617736A (zh) 2005-05-18
NO20042833L (no) 2004-08-12
NO336231B1 (no) 2015-06-22
CA2469092C (en) 2013-02-19
IS7296A (is) 2004-06-03
RU2303996C2 (ru) 2007-08-10
HU228207B1 (hu) 2013-01-28
NZ533356A (en) 2006-10-27
CN102151330B (zh) 2017-04-12
RU2004120536A (ru) 2005-03-27
DE60231131D1 (de) 2009-03-26
US7351686B2 (en) 2008-04-01
HUP0500039A2 (hu) 2005-03-29
CY1109044T1 (el) 2014-07-02
HK1067043A1 (en) 2005-04-01
PL205469B1 (pl) 2010-04-30
CA2469092A1 (en) 2003-06-12
WO2003047500A3 (en) 2004-03-18
PT1429800E (pt) 2009-04-27
IL160105A0 (en) 2004-06-20
PL370070A1 (en) 2005-05-16
CN102151330A (zh) 2011-08-17
JP4542339B2 (ja) 2010-09-15
JP2005515198A (ja) 2005-05-26
EP1429800A4 (de) 2006-03-22
EP1429800B1 (de) 2009-02-11
KR20040081431A (ko) 2004-09-21
AU2002353486A1 (en) 2003-06-17
HUP0500039A3 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
ATE422362T1 (de) Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose
DE69718150D1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
SE9302308L (sv) Proteinberedning
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
PL324531A1 (en) Derivatives of cyclosporin effective against hiv virus
DE60032250D1 (de) Behandlung von Allergien
WO2003061578A3 (en) Compositions for treatment or prevention of bioterrorism
DE60233898D1 (de) Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin-plasmaspiegeln
HUP0103078A2 (hu) Készítmények és eljárások szürkehályog kezelésére
ATE243750T1 (de) Leishmania-antigene zur anwendung in der leishmaniasis therapie und diagnose
EP1958960A3 (de) Verfahren für die Herstellung einer nicht-toxischen Anthrax-Impfung
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
PT1015595E (pt) Peptidos derivados da proteina de ligacao (g) do virus sincicial respiratorio
ATE515258T1 (de) Mukosales verabreichungssytem
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
NO20034453D0 (no) Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter
ATE415419T1 (de) Inaktivierte zytokine zur immunisierung
ATE296640T1 (de) Methode und mittel zur behandlung eines post- poliosyndroms
ATE349532T1 (de) Zytotoxisches t-zellepitop des papillomavirus l1- proteins und seine verwendung in diagnostik und therapie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1429800

Country of ref document: EP